Literature DB >> 17417651

Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy.

Ursula Grohmann1, Claudia Volpi, Francesca Fallarino, Silvia Bozza, Roberta Bianchi, Carmine Vacca, Ciriana Orabona, Maria L Belladonna, Emira Ayroldi, Giuseppe Nocentini, Louis Boon, Francesco Bistoni, Maria C Fioretti, Luigina Romani, Carlo Riccardi, Paolo Puccetti.   

Abstract

Glucocorticoid-induced tumor necrosis factor receptor (GITR) on T cells and its natural ligand, GITRL, on accessory cells contribute to the control of immune homeostasis. Here we show that reverse signaling through GITRL after engagement by soluble GITR initiates the immunoregulatory pathway of tryptophan catabolism in mouse plasmacytoid dendritic cells, by means of noncanonical NF-kappaB-dependent induction of indoleamine 2,3-dioxygenase (IDO). The synthetic glucocorticoid dexamethasone administered in vivo activated IDO through the symmetric induction of GITR in CD4(+) T cells and GITRL in plasmacytoid dendritic cells. The drug exerted IDO-dependent protection in a model of allergic airway inflammation. Modulation of tryptophan catabolism via the GITR-GITRL coreceptor system might represent an effective therapeutic target in immune regulation. Induction of IDO could be an important mechanism underlying the anti-inflammatory action of corticosteroids.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17417651     DOI: 10.1038/nm1563

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  122 in total

Review 1.  Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases.

Authors:  G C Prendergast; M Y Chang; L Mandik-Nayak; R Metz; A J Muller
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

Review 2.  Programming dendritic cells to induce T(H)2 and tolerogenic responses.

Authors:  Bali Pulendran; Hua Tang; Santhakumar Manicassamy
Journal:  Nat Immunol       Date:  2010-07-20       Impact factor: 25.606

Review 3.  How tolerogenic dendritic cells induce regulatory T cells.

Authors:  Roberto A Maldonado; Ulrich H von Andrian
Journal:  Adv Immunol       Date:  2010       Impact factor: 3.543

4.  Synergy between rapamycin and FLT3 ligand enhances plasmacytoid dendritic cell-dependent induction of CD4+CD25+FoxP3+ Treg.

Authors:  Moanaro Biswas; Debalina Sarkar; Sandeep R P Kumar; Sushrusha Nayak; Geoffrey L Rogers; David M Markusic; Gongxian Liao; Cox Terhorst; Roland W Herzog
Journal:  Blood       Date:  2015-04-01       Impact factor: 22.113

Review 5.  Learning from other diseases: protection and pathology in chronic fungal infections.

Authors:  Teresa Zelante; Giuseppe Pieraccini; Lucia Scaringi; Franco Aversa; Luigina Romani
Journal:  Semin Immunopathol       Date:  2015-09-17       Impact factor: 9.623

Review 6.  IDO-expressing regulatory dendritic cells in cancer and chronic infection.

Authors:  Alexey Popov; Joachim L Schultze
Journal:  J Mol Med (Berl)       Date:  2007-09-18       Impact factor: 4.599

Review 7.  The importance of NAD in multiple sclerosis.

Authors:  W Todd Penberthy; Ikuo Tsunoda
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

8.  Enhancement of T-cell-mediated anti-tumour immunity via the ectopically expressed glucocorticoid-induced tumour necrosis factor receptor-related receptor ligand (GITRL) on tumours.

Authors:  Jinhua Piao; Yosuke Kamimura; Hideyuki Iwai; Yujia Cao; Keisuke Kikuchi; Masaaki Hashiguchi; Taro Masunaga; Hongsi Jiang; Kouichi Tamura; Shimon Sakaguchi; Miyuki Azuma
Journal:  Immunology       Date:  2009-08       Impact factor: 7.397

9.  Reverse signaling using an inducible costimulator to enhance immunogenic function of dendritic cells.

Authors:  Gusheng Tang; Qin Qin; Peng Zhang; Guifang Wang; Menglei Liu; Qingli Ding; Yanghua Qin; Qian Shen
Journal:  Cell Mol Life Sci       Date:  2009-07-15       Impact factor: 9.261

Review 10.  The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses.

Authors:  Lindsay K Ward-Kavanagh; Wai Wai Lin; John R Šedý; Carl F Ware
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.